Uncommon Cents Investing LLC Sells 60 Shares of Elevance Health, Inc. (NYSE:ELV)

Uncommon Cents Investing LLC trimmed its holdings in Elevance Health, Inc. (NYSE:ELV) by 1.7% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 3,550 shares of the company’s stock after selling 60 shares during the quarter. Uncommon Cents Investing LLC’s holdings in Elevance Health were worth $1,674,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also modified their holdings of the company. Roundview Capital LLC lifted its stake in shares of Elevance Health by 2.9% in the first quarter. Roundview Capital LLC now owns 1,858 shares of the company’s stock valued at $912,000 after buying an additional 52 shares during the period. Moors & Cabot Inc. acquired a new position in Elevance Health in the 1st quarter valued at approximately $251,000. Baird Financial Group Inc. lifted its position in shares of Elevance Health by 0.4% in the 1st quarter. Baird Financial Group Inc. now owns 14,870 shares of the company’s stock worth $7,305,000 after acquiring an additional 57 shares during the period. Zions Bancorporation N.A. raised its stake in shares of Elevance Health by 52.1% in the first quarter. Zions Bancorporation N.A. now owns 893 shares of the company’s stock valued at $439,000 after purchasing an additional 306 shares in the last quarter. Finally, Brown Brothers Harriman & Co. lifted its position in Elevance Health by 102.9% in the first quarter. Brown Brothers Harriman & Co. now owns 846 shares of the company’s stock worth $416,000 after purchasing an additional 429 shares during the period. Institutional investors and hedge funds own 89.24% of the company’s stock.

Insider Buying and Selling

In other Elevance Health news, Director Ramiro G. Peru sold 753 shares of the stock in a transaction that occurred on Wednesday, February 7th. The shares were sold at an average price of $500.00, for a total transaction of $376,500.00. Following the transaction, the director now owns 9,109 shares in the company, valued at approximately $4,554,500. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. 0.35% of the stock is owned by insiders.

Elevance Health Trading Down 0.3 %

Shares of ELV stock opened at $518.52 on Friday. Elevance Health, Inc. has a 12-month low of $412.00 and a 12-month high of $521.18. The firm has a 50 day moving average price of $501.14 and a two-hundred day moving average price of $475.76. The company has a quick ratio of 1.44, a current ratio of 1.44 and a debt-to-equity ratio of 0.59. The company has a market capitalization of $120.66 billion, a PE ratio of 20.60, a price-to-earnings-growth ratio of 1.16 and a beta of 0.78.

Elevance Health (NYSE:ELV) last released its quarterly earnings results on Wednesday, January 24th. The company reported $5.62 earnings per share for the quarter, topping the consensus estimate of $5.60 by $0.02. Elevance Health had a return on equity of 20.47% and a net margin of 3.49%. The business had revenue of $42.45 billion during the quarter, compared to analysts’ expectations of $42.19 billion. During the same period last year, the firm posted $5.23 EPS. The firm’s revenue for the quarter was up 7.0% compared to the same quarter last year. As a group, analysts predict that Elevance Health, Inc. will post 37.15 earnings per share for the current year.

Elevance Health Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, March 22nd. Investors of record on Friday, March 8th were paid a $1.63 dividend. The ex-dividend date of this dividend was Thursday, March 7th. This is an increase from Elevance Health’s previous quarterly dividend of $1.48. This represents a $6.52 annualized dividend and a dividend yield of 1.26%. Elevance Health’s dividend payout ratio is 25.90%.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on ELV shares. Cantor Fitzgerald increased their price objective on shares of Elevance Health from $547.00 to $580.00 and gave the company an “overweight” rating in a research note on Wednesday, February 14th. Royal Bank of Canada raised their price target on shares of Elevance Health from $572.00 to $574.00 and gave the stock an “outperform” rating in a research note on Thursday, January 25th. StockNews.com cut Elevance Health from a “strong-buy” rating to a “buy” rating in a report on Thursday, January 25th. Finally, Barclays began coverage on Elevance Health in a research report on Wednesday, March 6th. They issued an “overweight” rating and a $584.00 price target on the stock. One equities research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat.com, Elevance Health presently has an average rating of “Moderate Buy” and an average price target of $569.36.

About Elevance Health

Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits.